Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $31.7400 (-4.28%) ($31.7400 - $31.7400) on Fri. Nov. 12, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.27% (three month average) | RSI | 50 | Latest Price | $31.7400(-4.28%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -2.3% a day on average for past five trading days. | Weekly Trend | TGTX advances 2.7% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(70%) ARKG(65%) IBB(62%) ARKK(61%) IWO(60%) | Factors Impacting TGTX price | TGTX will decline at least -1.635% in a week (0% probabilities). VIXM(-48%) VXX(-39%) UUP(-19%) UNG(-6%) TLT(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.635% (StdDev 3.27%) | Hourly BBV | -1.6 () | Intraday Trend | 0% | | | |
|
Resistance Level | $32.74 | 5 Day Moving Average | $33.51(-5.28%) | 10 Day Moving Average | $33.61(-5.56%) | 20 Day Moving Average | $32.74(-3.05%) | To recent high | -10.8% | To recent low | 46.4% | Market Cap | $4.02b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |